Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that CMIC, one of the largest contract research organizations (CROs) in Japan, has attained Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win^® program for CROs and other service providers. With this accreditation, CMIC can now offer a comprehensive suite of services to implement and support Medidata Rave^®, a leading platform for electronic clinical data capture, management and reporting, for a growing customer base in Japan, as well as across Asia.

Since starting its CRO business in 1992, CMIC has grown to become one of the largest CROs in Japan, with several locations throughout Asia and South America. CMIC offers services in several key areas of the clinical trial process, including monitoring and managing data, coordinating clinical research, consulting on pharmaceutical affairs and conducting pre-clinical work. With a vision of driving the development of evidence-based medicine, CMIC has long supported the use of cutting-edge technologies like Medidata Rave in the fast-growing Asian clinical trials market.

Medidata’s ASPire to Win program selects, trains and accredits clinical service providers to deliver Medidata Rave clinical trial technology along with their own project and data management expertise. The program offers CROs and service providers the choice of four enablement levels – Rave Aware, Rave Ready, Rave Accredited and Rave Accredited Plus. CMIC last year attained the Rave Accredited level, which allowed the company to build and configure its customers’ Rave studies, and provide a portfolio of other Rave-related services. As a Rave Accredited Plus member, CMIC now will be able to provide the full suite of Rave-related services, including end-user training, study build, reporting, outputs, integrations and migrations.

“The demand for Medidata Rave in Japan is strong, and as we extend our reach throughout Asia, we expect to see more opportunities to implement Rave and also to integrate Rave with a variety of clinical development technologies,” said Makoto Sato, Corporate Officer, CMIC. “We originally joined the ASPire to Win program because of Rave’s ease of use and rich functionality as well as its multi-language support that lends itself well to Asia’s multinational population. Now, as a Rave Accredited Plus partner, we will be able to independently offer an even broader set of Rave services to our customers.”

“We’re thrilled to deepen our relationship with CMIC, a leading Japanese CRO, and to further expand our joint presence in the Asia-Pacific region,” said Graham Bunn, Vice President for Global CRO Partnerships, Medidata Solutions. “Sponsors of clinical research across Asia will further benefit from CMIC’s extensive clinical experience and in-depth Rave expertise.”

Medidata first announced ASPire to Win in April 2005 as a partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include more than 20 partners, ranging from smaller clinical consultancies to large, global CROs. For more information about the ASPire to Win program, visit www.mdsol.com/partnerships/cros.htm.

About CMIC

CMIC (http://www.cmic.co.jp), which established its CRO business in 1992, has supported such drug development-related activities as monitoring, data management, recruiting of test subjects and clinical test coordination as Japan's first CRO. Capitalizing on the long years of experience and know-how as a CRO, it engages mainly in PVC (Pharmaceutical Value Creator) activities including CMO and CSO, in support of the value chains of pharmaceutical companies. CMIC has a presence not only in Japan but in Asia (China, Korea, Singapore and Taiwan), Brazil and U.S.A, and engages in a wide range of activities.

About Medidata Solutions Worldwide

Medidata Solutions (www.mdsol.com) is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer™), investigator benchmarking and budgeting (Medidata Grants Manager™), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor™), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave®). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.